After the introduction of anti-VEGF agents, IVI has become one of the most common procedures in ophthalmology in the treatment of conditions like exudative age-related macular degeneration, macular edema due to retinal vein occlusion, diabetic retinopathy, other types of choroidal neovascularization, vascular proliferative retinal diseases such as retinopathy of prematurity [2,3]. The gene discussed is VEGFA; the disease is diabetic retinopathy.